Exemestane for breast cancer prevention: A feasible strategy?

Keyphrases

• Exemestane 100%
• Breast Cancer Prevention 100%
• Feasible Strategy 100%
• Inactivator 66%
• Aromatase Inhibitors 66%
• Bone Metabolism 66%
• Placebo-controlled Study 33%
• Breast Cancer 33%
• Phase II Trial 33%
• Moderating Effect 33%
• Placebo 33%
• Monotherapy 33%
• Lipid Metabolism 33%
• Postmenopausal Women 33%
• Third Generation 33%
• Preventive Agent 33%
• Metastatic Breast Cancer 33%
• Detrimental Effects 33%
• Substantial Reduction 33%
• Contralateral Breast Cancer 33%
• Plasma Lipid Profile 33%
• Adjuvant Setting 33%
• Estrogen Suppression 33%

Medicine and Dentistry

• Breast Cancer Prevention 100%
• Exemestane 100%
• Breast Cancer 66%
• Aromatase Inhibitor 66%
• Bone Remodeling 66%
• Antiestrogen 33%
• Monotherapy 33%
• Lipid 33%
• Placebo-Controlled Study 33%
• Metastatic Breast Cancer 33%
• Postmenopause 33%
• Contralateral 33%
• Phase III and IV Trials 33%
• Placebo 33%
• Tamoxifen 33%
• Lipid Metabolism 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Exemestane 100%
• Breast Cancer 100%
• Lipid 66%
• Aromatase Inhibitor 66%
• Tamoxifen 33%
• Placebo 33%
• Placebo-Controlled Study 33%
• Metastatic Breast Cancer 33%
• Antiestrogen 33%
• Phase III and IV Trials 33%
• Monotherapy 33%